PureTech Health (LON:PRTC) Trading Up 14.6% – Time to Buy?

PureTech Health plc (LON:PRTC) shares traded up 14.6% on Friday . The company traded as high as GBX 118 ($1.53) and last traded at GBX 118 ($1.53). 1,623,564 shares changed hands during trading, an increase of 54% from the average session volume of 1,056,594 shares. The stock had previously closed at GBX 103 ($1.34).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 455 ($5.91) price target on shares of PureTech Health in a research note on Monday, December 16th.

PureTech Health Stock Performance

The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The firm has a 50-day moving average price of GBX 135.83 and a 200 day moving average price of GBX 148.25. The firm has a market capitalization of £354.45 million, a PE ratio of -4.84 and a beta of 1.02.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.